Clinical Trial

Olaparib in Patients With HRD Malignant Mesothelioma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
In this study, researchers will give olaparib (a drug) to mesothelioma patients who have specific changes in their DNA (known as gene mutations). Researchers will give this drug to each patient on the study to find out if it will help the patient's tumor shrink or stop growing.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2020-08-10; most recent amendment 2025-05-05.
Status change: Not Yet Recruiting → Recruiting 2021-05-12
Trial Details
NCT Number NCT04515836
Lead Sponsor University of Chicago
Collaborators: AstraZeneca
Conditions Mesothelioma, Homologous Recombination Deficiency
Enrollment 56 participants
Start Date 2021-02-19
Primary Completion 2028-04-15 (estimated)
Study Completion 2028-04-15 (estimated)
Updated on ClinicalTrials.gov 2025-05-06